サインイン 無料でサインアップします。

Last updated: 21 June 2024 at 4:18pm EST

Richard Croarkin Net Worth



Richard Croarkin biography

Richard J. Croarkin is Independent Director of Aerie Pharmaceuticals, Inc. Mr. Croarkin previously was Chief Financial Officer of Nestle Health Science, a division of Nestle focused on medicalized nutrition solutions for chronic medical conditions, from December 2010 to February 2013. From 2007 to 2010, Mr. Croarkin was Senior Vice President, Chief Financial Officer, and Corporate Strategy Officer at Alcon, which had annual sales of $7.1 billion and was the world’s leading ophthalmic pharmaceutical and medical device company before its acquisition by Novartis for $50 billion. In 2008 and 2009, Mr. Croarkin also served as a director on the supervisory board of the German publicly-traded company, WaveLight A.G., which manufactures and globally markets laser and diagnostic systems for refractive eye surgery. Previously, Mr. Croarkin was Executive Vice President and Chief Financial Officer of Nestle Waters North America, overseeing the finances of a business unit that grew to $4.4 billion in sales. Before joining Nestle, Mr. Croarkin worked for Pepsico Incorporated, where he served in a number of senior financial positions around the world, including as Chief Financial Officer of Pepsi Latin America and Pepsi Canada. Mr. Croarkin started his career with AMAX, Inc., where he worked in treasury, corporate development and planning. Mr. Croarkin currently serves as a member of the board of directors of Clearside Biomedical, a company advancing eye disease therapies by delivering drugs to the suprachoroidal space via a proprietary microinjector. He also serves on occasion as a panelist on the NASDAQ Listing Qualifications Panel. In 2018, Mr. Croarkin was elected to the Board of Waveny LifeCare Network, Inc., a not-for-profit nursing home and healthcare provider for Southwestern Connecticut’s senior population. Mr. Croarkin received his B.A. in Economics from Georgetown University and his M.B.A. in Finance from the University of Connecticut.

What is the salary of Richard Croarkin?

As the Independent Director of Aerie Pharmaceuticals Inc, the total compensation of Richard Croarkin at Aerie Pharmaceuticals Inc is 321,746$. There are 15 executives at Aerie Pharmaceuticals Inc getting paid more, with Vicente Anido having the highest compensation of 5,529,670$.



How old is Richard Croarkin?

Richard Croarkin is 65, he's been the Independent Director of Aerie Pharmaceuticals Inc since 2015. There are 6 older and 15 younger executives at Aerie Pharmaceuticals Inc. The oldest executive at Aerie Pharmaceuticals Inc is Gerald Cagle, 75, who is the Independent Director.

What's Richard Croarkin's mailing address?

Richard's mailing address filed with the SEC is C/O CLEARSIDE BIOMEDICAL, INC., 900 NORTH POINT PARKWAY, SUITE 200, ALPHARETTA, GA, 30005.

Insiders trading at Aerie Pharmaceuticals Inc

Over the last 11 years, insiders at Aerie Pharmaceuticals Inc have traded over 194,685,628$ worth of Aerie Pharmaceuticals Inc stock and bought 2,240,245 units worth 39,233,665$ . The most active insiders traders include Group Holdings (Sbs) Adviso...、Anand Mehra、Capital Management Ii, Llc .... On average, Aerie Pharmaceuticals Inc executives and independent directors trade stock every 45 days with the average trade being worth of 2,718,618$. The most recent stock trade was executed by Casey C. Kopczynski on 15 February 2021, trading 60,651 units of AERI stock currently worth 12,130$.



What does Aerie Pharmaceuticals Inc do?

Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. Aerie's first product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie's second product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose combination of Rhopressa® and the widely-prescribed PGA (prostaglandin analog) latanoprost, was launched in the United States in May 2019. In clinical trials of Rocklatan®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for wet age-related macular degeneration and diabetic macular edema.



What does Aerie Pharmaceuticals Inc's logo look like?

Aerie Pharmaceuticals Inc logo

Aerie Pharmaceuticals Inc executives and stock owners

Aerie Pharmaceuticals Inc executives and other stock owners filed with the SEC include: